Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.10, read 2026-10-28
Ethical does not pass the values gate
Price22.37 USD
Fair value36.50
Ethical score70.0/100
Our investment reviews on this name
2026-10-28Read Markup23.01-2.8% to today Distribution gives way to Markup after a 25% rise in 7 days
2026-10-21Read Distribution18.38+21.7% to today Markdown gives way to Distribution after a 23% slide in 5 weeks
2026-09-16Read Markdown23.88-6.3% to today ✓Markup gives way to Markdown after a 46% rise in 11 weeks
2026-07-02Read Markup16.35+36.8% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Viridian Therapeutics, Inc. holds its Markup at $22.37. Consolidating, no directional conviction, held for 68 days.
As held on the ledger · 2026-10-23
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 68 days
Price at the screen
$22.37
Valuation
N/A trailing · -8.35 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.10
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.64%
Below 33%
Interest-bearing debt is just 5.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
73.63%
Below 33%
Interest-bearing cash and securities are 73.6% of assets, above the one-third limit.
Fail
Receivables
23.61%
Below 49%
Money owed to the company is 23.6% of assets, under the 49% limit.
Pass
Revenue purity
38.67%
Below 5%
38.7% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Viridian Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 74% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when VRDN's ethical verdict changes
Today VRDN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 63.2% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus Strong Buy. The average target sits +63% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
VRDN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup · changed$23.01+25.2%Entry 9
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 25.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (16 analysts) rates it strong buy, with a mean price target of $34. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (16 analysts) rates it strong buy, with a mean price target of $34.
2026-10-14Markdown$18.66-15.2%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (16 analysts) rates it strong buy, with a mean price target of $34.
2026-10-02Markdown$22.00-7.9%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 7.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (16 analysts) rates it strong buy, with a mean price target of $34.
2026-09-16Markdown · changed$23.88+4.4%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (16 analysts) rates it strong buy, with a mean price target of $34.
2026-08-16Markup$22.88+39.9%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 39.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (16 analysts) rates it strong buy, with a mean price target of $34.
2026-07-18Markup$16.35+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (16 analysts) rates it strong buy, with a mean price target of $34.
2026-07-03Markup$16.35+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$16.35Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
